natgillin/translations-raw huggingface dataset:
Medbring AZILECT æsken/beholderen, når De opsøger Deres læge/skadestue eller apotek.
Take the AZILECT carton/bottle with you to show the doctor or pharmacist.
Medbring for en sikkerheds skyld altid et ekstra injektionssystem i tilfælde af, at din FlexPen mistes eller ødelægges.
As a precautionary measure, always carry a spare insulin delivery device in case your FlexPen is lost or damaged.
Medbring for en sikkerheds skyld altid et ekstra insulindispenseringssystem i tilfælde af, at den FlexPen du har i brug, mistes eller ødelægges.
As a precautionary measure, always carry a spare insulin delivery device in case your FlexPen in use is lost or damaged.
Medbring for en sikkerheds skyld altid et ekstra insulindispenseringssystem i tilfælde af, at du mister eller beskadiger din InnoLet.
As a precautionary measure, always carry a spare insulin delivery device in case your InnoLet in use is lost or damaged.
Medbring for en sikkerheds skyld altid glucosetabletter, slik, kiks eller frugtjuice.
Always carry glucose tablets or high sugar snacks with you, just in case.
Medbring Rasagilin ratiopharm æsken/beholderen, når De opsøger Deres læge/skadestue eller apotek.
Take the Rasagiline ratiopharm carton/bottle with you to show the doctor or pharmacist.
Medbringe for en sikkerheds skyld altid et ekstra injektionssystem i tilfælde af, at din InnoLet mistes eller ødelægges.
As a precautionary measure, always carry a spare insulin delivery device in case your InnoLet is lost or damaged.
meddasabu
induction by
MedDRA
ystem organ class
MedDRA konventioner for hyppighed er meget almindelig ((1/10), almindelig ((1/100 til <1/10), ualmindelig (1/1.000 til <1/100), sjælden (1/10.000 til <1/1.000) eller meget sjælden (<1/10.000) eller ikke kendt (kan ikke estimeres ud fra forhåndenværende data) , inklusive enkeltstående rapporteringer.
MedDRA conventions for frequency are very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data) including isolated reports.
MedDRA organklasse Bivirkning Immunsystemet
MedDRA system organ class Adverse reaction Immune system disorders
MedDRA Organklasse- system
MedDRA System Organ Class
MedDRA Standard Systemorganklasse
MedDRA Standard System Organ Class
MedDRA system- organklasse
MedDRA system organ class
MedDRA system- organklasse (SOC)
MedDRA System Organ Class (SOC)
MedDRA Systemorgan klasse
MedDRA system organ classes
MedDRA systemorgan- klasse
MedDRA system organ class
MedDRA Systemorgan- klasse
MedDRA system organ classes
MedDRA systemorgan-klass e
MedDRA system organ class
MedDRA Systemorganklasse
MedDRA Organ system classes
MedDRA Systemorganklasse (SOK)
abdominal pain
MedDRA Systemorganklasser
MedDRA Organ system classes
MedDRA term
MedDRA Preferred Term
MedDRA termer
MedDRA Preferred Term
MedDRA-
Cough
MedDRA-
Peripheral oedema
MedDRA-
System Organ Class
MedDRA-databasen
12.0%);
MedDRA-databasen
MedDRA system
MedDRA-databasen
MedDRA system organ classes
MedDRA-organklassificering
MedDRA System Organ Classes
MedDRA-standardterm
MedDRA Preferred Term
MedDRA-syste morganklasse
MedDRA System Organ Class
MedDRA-system organklasse (V14.0)
Reproductive system and breast disorders
MedDRA-system- organklasse
MedDRA System Organ Class
MedDRA-systemorganklasse
Frequency category
MedDRA-systemorganklasse
MedDRA SOC
MedDRA-systemorganklasse
MedDRA Standard System Organ Class
MedDRA-systemorganklasse
MedDRA system organ classes
MedDRA-Systemorganklasse
System Organ Class
MedDRA-systemorganklasse Hyppighedskategori
exanthematous pustulosis
MedDRA-term
MedDRA term
MedDRA= Medical Dictionary for Regulatory Activities.
MedDRA  Medical Dictionary for Regulatory Activities.
Medens barnet er inde i sin moders mave, har det ingen brug for sine lunger.
While a baby is inside its mother’s womb it does not need to use its lungs.
Medens De stadig holder pennen lodret, trykkes den sorte doseringsknap ind igen, og hold øje med, at der kommer en dråbe lægemiddel til syne i kanylespidsen.
While still holding the pen in the upright position, push in the black dose knob again and watch the needle tip for a drop of medicine to appear.
Medens der i de kontrollerede kliniske forsøg ikke blev observeret en forøget risiko, har der været post- marketing rapporter om gastriske og duodenale sår, i visse tilfælde alvorlige og med komplikationer, i forbindelse med brug af orale bifosfonater.
While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications.
Medens der i de kontrollerede kliniske studier ikke blev observeret en forøget risiko, har der været post- marketing rapporter om gastriske og duodenale sår, i visse tilfælde alvorlige og med komplikationer, i forbindelse med brug af orale bisphosphonater.
While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications.
Medens der i de kontrollerede kliniske studier ikke blev observeret en forøget risiko, har der været post-marketingrapporter om gastriske og duodenale sår, i visse tilfælde alvorlige og med komplikationer, i forbindelse med brug af orale bisphosphonater.
While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications.
Medens feber kan være en del af det influenzalignede syndrom, som ofte rapporteres under behandling med interferon, skal andre årsager til vedvarende feber udelukkes, specielt alvorlige infektioner (bakterielle, virale og fungale), især hos patienter med neutropeni.
While fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever, particularly serious infections (bacterial, viral, fungal) must be ruled out, especially in patients with neutropenia.
Medens pennen stadig holdes opret, skubbes den sorte doseringsknap ind, indtil den klikker i position.
While still holding the pen in the upright position, push in the black dose knob until it clicks into position.
medfødt agammaglobulinæmi og hypogammaglobulinæmi
congenital agammaglobulinaemia and hypogammaglobulinaemia
Medfødt aids med recidiverende bakterieinfektioner.
Congenital AIDS with recurrent bacterial infections.
Medfødt aids og recidiverende bakterieinfektioner.
Congenital AIDS and recurrent bacterial infections.
medfødt eller dokumenteret erhvervet QT-forlængelse
congenital or documented acquired QT prolongation
Medfødt eller dokumenteret QTc-forlængelse.
Congenital or documented acquired QTc prolongation
Medfødt hjertelidelse, hvor åbenheden af ductus arteriosus er nødvendig for tilfredsstillende pulmonær eller systemisk blodgennemstrømning (f.eks. pulmonær atresi, svær acyanotisk Fallot, svær coarctatio af aorta);
Congenital heart disease in which patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow (e.g. pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta);
medfødt hjertesygdom såsom atriale og ventrikulære septum defekter;
Congenital heart disease such as atrial and ventricular septal defects;
medfødt hjertesygdom såsom atriale og ventrikulære septumdefekter;
Congenital heart disease such as atrial and ventricular septal defects;
Medfødt langt QT-syndrom.
Congenital long QT syndrome.
Medfødt langt QTc-syndrom.
Congenital long QTc syndrome.
Medfødt neutropeni:
Congenital neutropenia:
medfødt plexus choriodeus-cyste;
congenital choroid plexus cyst;
Medfødt, idiopatisk eller cyklisk neutropeni: Filgrastim skal gives som subkutan injektion.
Congenital, idiopathic or cyclic neutropenia ; filgrastim should be given by subcutaneous injection.
Medfødte abnormiteter (fødselsdefekter) har været rapporteret hos børn, hvis mødre tog mercaptopurin, særligt i kombination med andre lægemidler mod kræft.
Congenital abnormalities (birth defects) have been reported in babies whose mothers took mercatopurine, particularly in combination with other cancer medicines.
medfødte eller erhvervede blødningsforstyrrelser
congenital or acquired bleeding disorders
Medfødte eller erhvervede klapdefekter med klinisk relevante forstyrrelser af myokardiefunktionen, som ikke er relateret til pulmonal hypertension.
Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
Medfødte eller erhvervede koagulationsforstyrrelser
Congenital or acquired coagulation disorders
Medfødte misdannelser rapporteret hos spædbørn født efter en FTET-cyklus
Congenital malformations reported in infants born after a frozen-thawed embryo transfer (FTET) cycle
Medfødte sygdomme
Congenital disorders
Medfødte, familiære og genetiske sygdomme
Congenital and familial and genetic disorders
Medfødte, familiære og genetiske sygdomme
Congenital and familial/genetic disorders
Medfødte, familiære og genetiske sygdomme
Congenital, and familial and genetic disorders
Medfødte, familiære og genetiske sygdomme
General disorders and administration site conditions
Medfødte, familiære og genetiske sygdomme
Surgical and medical procedures
medfølger ikke i pakningen en steril injektionssprøjte med en 19 (19G) eller bredere kanyle til udtrækning af solvensen en steril injektionssprøjte med en 26 Gauge (26G) kanyle til injektionen
not supplied in the pack one sterile injection syringe with 19 (19G) or wider Gauge needle to withdraw the solvent one sterile injection syringe with 26 Gauge (26G) needle for the injection
Medfølger IKKE i æsken
NOT supplied in the pack
medføre signifikant fald i atazanavirs
expected to result in significant
medføre subterapeutiske
may result in subtherapeutic
Medførte seponering
Related discontinuations
Medi an samlet overlevelse = 6,0
Median OS = 6.0 months
Median
Median (m)
Median
Median TTF: 2.6
Median # tidligere
Median # previous NRTIs
Median # tidligere NRTI’er
Median # previous NRTIs
Median % ændring i T2- hyperintense læsioners volumen
Median % change in T2- hyperintense lesion volume
Median %-ændring i volumen af MRI-T2-
Median % change in MRI-T2 lesion volume
Median (25., 75. percentil) dage med WHO Grad 2/3/4 oral mucositis**
Median (25th, 75th percentile) days of WHO Grade 2/3/4 oral mucositis
Median (25., 75. percentil) dage med WHO Grad 3/4 oral mucositis hos berørte patienter
Median (25th, 75th percentile) days of WHO Grade 3/4 oral mucositis in affected patients
Median (25., 75. percentil) dage med WHO Grad 3/4 oral mucositis**
Median (25th, 75th percentile) days of WHO Grade 3/4 oral mucositis
Median (25., 75. percentil) kumulativ dosis
Median (25th, 75th percentile)
Median (95 % C.I)
Median (95% C.I.)
Median (95 % C.I.)
Median (95% C.I.)
Median (95 % CI)
HR (95% CI)
Median (95 % CI)
Median (95% C.I.)
Median (95 % CI)
Median (95% CI)
Median (95 % Cl) N=68)
Median (95% Cl) N=68
Median (95% CI) (måneder)
Median (95% CI) (months)
Median (95% CI) (måneder) 3,48 (2,14; 4,86) 2,83 (2,10; 3,52)
Median (95% CI) (months) 3.48 (2.14, 4.86) 2.83 (2.10, 3.52)
Median (95% CI) måneder
Median (95% CI) months
Median (95% CI) måneder 12,19 (9,66; 14,98) 9,36 (8,05; 10,68)
Median (95% CI)months 12.19 (9.66, 14.98) 9.36 (8.05, 10.68)
Median (interval)
Median (range)
Median (middel) % ændring i hjernevolumen i løbet af 12 måneder
Median (mean) % change in brain volume over 12 months
Median (middel) % ændring i hjernevolumen i løbet af 24 måneder
Median (mean) % change in brain volume over 24 months
Median (middel) antal Gd-opladende læsioner ved måned 24
Median (mean) number of Gd-enhancing lesions at Month 24
Median (middel) antal nye eller forstørrede T2- læsioner i løbet af 12 måneder
Median (mean) number of new or enlarging T2 lesions over 12 months
Median (middel) antal nye eller forstørrede T2- læsioner i løbet af 24 måneder
Median (mean) number of new or enlarging T2 lesions over 24 months
Median (middel) antal nye eller forstørrrede T2- læsioner i løbet af 24 måneder
Median (mean) number of new or enlarging T2 lesions over 24 months
median (min.,
median (min, max)
Median (min; maks): alle patienter
Median (min, max): all patients
Median (minimum-maksimal)
Median (minimum – maximum)
Median (minutter)
Median (minutes)
Median (måneder) responsvarighed (95% konfidensinterval)
Median duration (months) of DOR (95% CI) HR (95% CI)
Median (måneder)1
Median (months)1
Median (område)
Median (Range)
Median (Rangel)
Median (Range)
Median (uger) (95 % konfidensinterval)
Median (weeks) (95 % CI)
Median 23,3 (95% CI:
Median 23.3 (95% CI:
Median 95% konfidensinterval
Median 95% CI
Median [2,5 – 97,5 % interval]
Median [2.5 – 97.5% range]
Median [95 % KI], måneder
Median [95% CI]. months
median [95 %-
Median [95% CI], weeks
median [95 %- konfidensinterval], uger
Median [95% CI], weeks
Median af antallet af eksemudbrud justeret for ’time at risk’ (% patienter uden nogen eksemudbrudsperioder)
Median number of DEs adjusted for time at risk (% of patients without any DE periods)
Median af antallet af eksemudbrud som kræver betydelig intervention justeret for ’time at risk’ (% af patienter uden eksemudbrud krævende betydelig intervention)
Median number of DEs requiring substantial intervention adjusted for time at risk (% of patients without DE requiring substantial intervention)
Median af samlet overlevelse
Median overall survival
Median af samlet overlevelse var 20,6 uger [95 % Cl: 10,4 – 36,4].
Median overall survival was 20.6 weeks [95 % CI: 10.4–36.4].
Median af tiden til første eksemudbrud
Median time to first DE
Median af tiden til første eksemudbrud krævende betydelig
Median time to first DE requiring substantial intervention
Median af tiden til første eksemudbrud krævende betydelig intervention
Median time to first DE requiring substantial intervention
Median alder (interval), år
Median age (range), years
Median alder for ”intent-to-treat-populationen” var 73 år (interval 64 til 91 år).
The median age for the intent-to-treat (ITT) population was 73 years (range 64 to 91 years).
Median annualiseret blødningshyppighed hos forsøgspersoner, der kunne evalueres for virkning, var 1,60 (interkvartilt interval 0,0-4,69) for personer i armen med individualiseret profylakse, 3,59 (1,86-8,36) for forsøgspersoner i armen med ugentlig profylakse og 33,57 (21,14-48,69) for forsøgspersoner i armen med behandling ved behov.
Median annualised bleeding rates in subjects evaluable for efficacy were 1.60 (interquartile range 0.0-4.69) for subjects in the individualised prophylaxis arm, 3.59 (1.86-8.36) for subjects in the weekly prophylaxis arm and 33.57 (21.14-48.69) for subjects in the on demand treatment arm.
Median baseline CD4+ celletal (interval), x 106 celler/l
Median baseline CD4+ cell count (range), x 106 cells/L
Median baseline CD4+ celletal, celler/mm3 (IQR)
Median Baseline CD4+ Cell Count, cells/mm3 (IQR)
Median baseline CD4+-celletal (celler/mm3) (interval, celler/mm3)
Median Baseline CD4+ Cell Count (cells/mm3) (range, cells/mm3)
Median baseline hiv-1 RNA, log10 kopier/ml (IQR)
Median Baseline HIV-1 RNA, log10 copies/ml (IQR)
Median baseline hiv-1-RNA, log10 kopier/ml (IQR)
Median Baseline HIV-1 RNA, log10 copies/ml (IQR)
Median baseline plasma hiv 1-rna (interval) log10 kopier/ml
Median baseline plasma HIV-1 RNA (range), log10 copies/mL
Median behandlingstid med imatinib i dage
Median time of imatinib treatment in
Median behandlingsvarighed for alle patienter var 8,6 måneder (mellem 0 til 44,1 måned).
The median duration of treatment for all patients was 8.6 months (range 0 to 44.1).
Median behandlingsvarighed med dasatinib var 3 måneder med 2% behandlet i > 24 måneder til dato.
Median duration of treatment on dasatinib was 3 months with 2% treated for > 24 months to date.
Median behandlingsvarighed med dasatinib var 3 måneder med 7% af patienterne behandlet i > 24 måneder til dato.
Median duration of treatment on dasatinib was 3 months with 7% of patients treated for > 24 months to date.
Median behandlingsvarighed og daglige dosis, samt hyppigheden af dosismodifikationer var sammenlignelige med placebobehandlede patienter med PS≥2 (8,3 %).
The median treatment duration and daily dose, as well as the rate of dose modification and dose reduction were similar to those observed in patients with a reported PS ≥ 2 receiving placebo (8.3%).
Median CD4 celler/μl
Median CD4 cells/μl
Median CD4+ celletal (interval), x 106 celler/l ved baseline
Median baseline CD4+ cell count (range), x 106 cells/l
Median CD4+ celletal ved baseline (interval), celler/mm3
Median baseline CD4+ cell count (range), cells/mm3
Median CD4+ celletal ved baseline var 352 celler/mm3 (1-1.455) og 16,9% havde CD4+ celletal 200 celler/mm3.
The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts 200 cells/mm3.
Median CD4+ celletalsændring fra baseline (x 106/l)c
median CD4+ cell count change from baseline (x 106/l)c
Median cumulative illness rating score for geriatrics (CIRS-G) var 9 og 31 % af patienterne havde CIRS-G > 10.
Median Cumulative Illness Rating Score for Geriatrics (CIRS-G) was 9, and 31% of patients had a CIRS-G >10.
Median cumulative illness rating score for geriatrics (CIRS-G) var 9, og 31 % af patienterne havde CIRS-G >10.
Median cumulative illness rating score for geriatrics (CIRS-G) was 9 and 31% of patients had a CIRS-G >10.
Median DoRc
DoRc (months)
Median follow-up (år)
Median Follow-up (yrs)
Median for den gennemsnitlige ugentlige dosis for splenektomerede patienter var 3 µg/kg, og den var 2 µg/kg for ikke-splenektomerede patienter.
The median average weekly dose for splenectomised patients was 3 µg/kg and for non-splenectomised patients was 2 µg/kg.
Median for investigatorbedømt PFS var 30,7 måneder i BzmbR-CAP-gruppen og 16,1 måneder i R- CHOP-gruppen (hazard-ratio [HR]=0,51; p < 0,001).
Median PFS by investigator assessment was 30.7 months in the BzmbR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51; p < 0.001).
Median for patienternes trombocyttal var 14 x 109/l ved optagelse i undersøgelsen.
Patients had a median platelet count of 14 x 109/l at study entry.
Median for progressionsfri overlevelse (95 % CI), måneder
Median Progression-Free Survival (95% CI), (months)
Median forskel (95 % konfidensinterval)
Median difference (95% CI)
Median gennemsnitsdosis pr. injektion til at behandle en blødningsepisode var 46,07 (interkvartilt interval 32,86-57,03) IU/kg.
The median average dose per injection to treat a bleeding episode was 46.07 (interquartile range 32.86-57.03) IU/kg.
Median gennemsnitsdosis pr. injektion til at opretholde hæmostase under operationen var 94,7 IU/kg (interval 49 til 152 IU/kg).
The median average dose per injection to maintain hemostasis during surgery was 94.7 IU/kg (range: 49 to 152 IU/kg).
Median HBV-dna- reduktion fra baselinec (log10 kopier/ml)
Median HBV DNA reduction from baselinec (log10 copies/ml)
Median HCV-RNA ved baseline (log10 IE/ml)
Median baseline HCV RNA levels (log10 IU/ml)
Median hiv 1-RNA (interval), log10 kopier/ml i plasma ved baseline
Median baseline plasma HIV-1 RNA (range), log10 copies/ml
Median hiv-1 RNA i plasma
Median plasma HIV-1 RNA
Median hiv-1 RNA i plasma ved baseline var 3,9 log10 kopier/ml, og mediant CD4-celletal var 385 x 106 celler/l.
The median baseline plasma HIV-1 RNA was 3.9 log10 copies/ml, and the median baseline CD4 cell count was 385 x 106 cells/l.
Median HIV-1-RNA (log10 kopier/ml) (interval)
Median HIV-1 RNA (log10 copies/ml) (range)
Median i måneder (interval)
Median in months (range)
Median opfølgning 12 måneder*
Median follow-up 12 months
Median opfølgning 8 år**
Median follow-up 8 years
Median opfølgning var 14,2 måneder. g Data cut-off dato for den endelig analyse for samlet overlevelse var 28. august 2015 og median opfølgning var 18,5 måneder-.
The median follow up was 14.2 months. g The data cut-off date for the final OS analysis is 28 August 2015 and median follow-up was 18.5 months.
Median opfølgningsperioden var 0,8 år (incidens 5,7 % [95 % CI
The median duration of follow-up was 0.8 years (incidence 5.7% [95% CI 2.65%-10.6%].
Median opfølgningstid var 1,8 år i AC→P- armen og 2,0 år i AC→PH-armen.
Median duration of follow up was 1.8 years in the AC→P arm and 2.0 years in the AC→PH arm
Median OS (95% CI) (måneder)
Median OS (95% CI) (months)
Median OS (måneder) (95 % CI)
OS Median (months) (95% CI)
Median OS (måneder)a [95% CI]b
Median OS (months)a [95% CI]b
Median OS [måneder]
Median OS [months]
Median OS blev ikke nået for begge grupper. p < 0,005 for OS.
Median OS not reached for both arms. p < 0.005 for OS.
Median OS i ITT-populationen var 72,7 uger og 64,9 uger (HR 0,876; 95% CI: 0,679-1,129; p = 0,306) i henholdsvis sunitinib-armen og placebo-armen.
Median OS in the ITT population was 72.7 weeks and 64.9 weeks (HR 0.876, 95% CI: 0.679 – 1.129, p = 0.306), in the sunitinib and placebo arms respectively.
Median OS i måneder (95% CI)
Median OS in months (95% CI)
Median OS i måneder [95% CI] 43,7 [40,34; NE (ikke estimerbar)]
Median OS in months [95% CI] 43.7 [40.34, NE] 39.6 [33.25,NE]
Median OSd i måneder (95% CI)
Median OS d in months
Median overlevelse
Median Survival
Median overlevelse (i måneder) (95 % KI)
Median survival (months) (95% CI)
Median overlevelse (måneder)
Median overall survival
Median overlevelse (måneder)
Median overall survival (months) (95 % CI)
Median overlevelse (måneder)
Median survival (months)
Median overlevelse (måneder) (95 % CI)
Median overall survival
Median overlevelse (måneder) (95 % CI)
Median overall survival in months (95% CI)
Median overlevelse (måneder) (95 % CI)
Median progression free survival (months) (95%CI)
Median overlevelse (måneder) (95 % KI)
Median survival (months) (95% CI)
Median overlevelse (OS)
Median overall survival (months)
Median overlevelse (OS) (måneder)
Median overall survival (months)
Median overlevelse (uger) (95 % CI)
Median survival (weeks) (95% CI)
Median overlevelse i alt (måneder) (95% CI)
Median overall survival (months)
Median overlevelse i alt var også signifikant længere til fordel for TPF-armen sammenlignet med PF- armen (median OS: 18,6 vs.
Median overall survival was also significantly longer in favor of the TPF arm compared to the PF arm (median OS: 18.6 vs.
Median overlevelse i alt var også signifikant længere til fordel for TPF-armen sammenlignet med PF-armen (median OS: 18,6 vs.
Median overall survival was also significantly longer in favor of the TPF arm compared to the PF arm (median OS: 18.6 vs.
Median overlevelse i alt var også signifikant længere til fordel for TPF-armen sammenlignet med PF-armen (median overlevelse i alt: 18,6 vs.
Median overall survival was also significantly longer in favour of the TPF arm compared to the PF arm (median OS: 18.6 vs.
Median overlevelse ialt var også signifikant længere til fordel for TPF-armen sammenlignet med PF-armen (median OS: 18,6 vs.
Median overall survival was also significantly longer in favor of the TPF arm compared to the PF arm (median OS: 18.6 vs.
Median overlevelse, måneder (95 % KI)
Median survival, months (95% CI)
Median overlevelse1, måneder
Median overall survival1, months
Median overlevelsestid
Median survival (months)
Median overlevelsestid (måneder) 1-års overlevelse (%)
Median survival (months) 1-year Survival (%)
Median overlevelsestid (måneder) 95 % CI
Number of patients Median survival (months) 95% CI
Median PFO (måneder)
Median PFS (months)
Median PFS (95% CI) (måneder)
Median overall survival (95% CI) (months)
Median PFS (95% CI) (måneder)
Median PFS (95% CI) (months)
Median PFS (antal uger) (95 % CI)
Median PFS, weeks (95% CI)
Median PFS (i behandling)**
Median PFS (on treatment)
Median PFS (mdr.) (95 % CI)
Median PFS (months) (95% CI)
Median PFS (måneder)
Median PFS (months) Hazard Ratio (95% CI)4
Median PFS (måneder) (95 % CI)
PFS median (months) (95% CI)
Median PFS (måneder) 2
Median PFS (months) 2
Median PFS (måneder)1
Median PFS (months)1
Median PFS (måneder)a [95% CI]b
Median PFS (months)a [95% CI]b
Median PFS (måneder.) (95 % CI)
Median PFS (months) (95% CI)
Median PFS [måneder]
Median PFS [months]
Median PFS a,b i måneder (95% CI)
Median PFS a,b in months
Median PFS i måneder (95 % CI)
Median PFS in months (95% CI)